Cubicin.com

CUBICIN length of stay and costs in complicated skin infections

In two studies, CUBICIN demonstrated comparatively less resource utilization for patients with complicated skin infections1,2
Significantly shorter antibiotic-related length of stay (AR-LOS) and lower absolute costs of hospitalization with CUBICIN vs vancomycin for patients with complicated skin infections*

Significantly shorter antibiotic-related length of stay (AR-LOS) and lower absolute costs of hospitalization with CUBICIN vs vancomycin for patients with complicated skin infections*

* A prospective, open-label, single-center study of CUBICIN 4 mg/kg daily in patients with complicated skin and skin structure infections (cSSSI) compared with matched historical controls receiving vancomycin.
† Antibiotic-related length of stay was defined as the difference between the day antibiotics were started for cSSSI and the day of discontinuation.
‡ Cost data included institutional hospital charges (drug costs were obtained from the average wholesale prices in the 2006 Red Book).

Overall total costs for treatment of MRSA complicated skin infections(2)

Overall total costs for treatment of MRSA complicated skin infections(2)

Retrospective, single-center study comparing daptomycin, linezolid, and vancomycin in patients with MRSA cSSSI. Overall costs calculated based on overall charges incurred for treatment, including both drug expenditures and hospital charges.

CUBICIN treatment costs for MRSA bacteremia
Total cost data for CUBICIN vs vancomycin

In a post hoc analysis of data from a phase 3 trial evaluating CUBICIN in Staphylococcus aureus bacteremia, relative costs of treatment were compared in the subset of patients with MRSA receiving either CUBICIN 6 mg/kg or vancomycin3*

Mean total costs (and standard deviation [SD])† during hospital stay

* Patients in the prespecified MRSA subgroup of the comparator treatment arm were to receive vancomycin + 4 days of initial low dose gentamicin. The gentamicin costs were included in this analysis.4
† Total costs included study drug acquisition, infusions, medications/procedures associated with drug-related adverse events, therapeutic drug monitoring and treatment failures, and hospital beds. Drug costs were based on 2006 Red Book (CUBICIN $0.365/mg, vancomycin $7.00/g). Procedure and laboratory costs were based on typical community hospital costs. The hospital stay per diem costs were calculated assuming ICU, step-down, and ward bed charges of $1300, $800, and $550, respectively.

Download the Cost Data for CUBICIN

References: 1. Davis SL, McKinnon PS, Hall LM, et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: Clinical and economic outcomes. Pharmacotherapy. 2007;27:1611-1618. 2. Fossaceca C. Retrospective review of clinical and pharmacoeconomic outcomes associated with daptomycin, vancomycin, and linezolid usage in the treatment of complicated skin and skin structure infections. Poster presented at: 2007 Summer Meeting of the American Society of Health-System Pharmacists; June 24-27, 2007; San Francisco, CA. Poster P53E. 3. Bhavnani SM, Prakhya A, Hammel JP, Ambrose PG. Cost-effectiveness of daptomycin and vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Poster presented at: 45th Annual Meeting of IDSA; October 4-7, 2007; San Diego, CA. Poster 1112. 4. Fowler VG Jr, Boucher HW, Corey GR, et al; the S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.

Indications and Important Safety Information

CUBICIN® (daptomycin for injection) is indicated for the following infections:
- Complicated skin and skin structure infections caused by susceptible isolates of the following Gram-positive microorganisms: S. aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subspecies equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms
- S. aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms
The efficacy of CUBICIN in patients with left-sided infective endocarditis due to S. aureus has not been demonstrated. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor. CUBICIN has not been studied in patients with prosthetic valve endocarditis or meningitis
Patients with persisting or relapsing S. aureus infection or poor clinical response should have repeat blood cultures. If a culture is positive for S. aureus, MIC susceptibility testing of the isolate should be performed using a standardized procedure, as well as diagnostic evaluation to rule out sequestered foci of infection. Appropriate surgical intervention (eg, debridement, removal of prosthetic devices, valve replacement surgery) and/or consideration of a change in antibiotic regimen may be required
CUBICIN is not indicated for the treatment of pneumonia
Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of nearly antibacterial agents, including CUBICIN, and may range in severity from mild diarrhea to fatal colitis. CDAD has been reported to occur over 2 months post-antibiotic treatment. If CDAD is suspected, antibiotic treatment may need to be suspended
Patients receiving CUBICIN should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. In patients who receive CUBICIN, creatine phosphokinase (CPK) levels should be monitored weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-CoA reductase inhibitor. In patients with renal insufficiency, both renal function and CPK should be monitored more frequently. Patients who demonstrate unexplained elevations in CPK while receiving CUBICIN should be monitored more frequently
CUBICIN should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK elevation >1000 U/L (~5 x ULN), or in patients without reported symptoms who have marked elevations in CPK >2000 U/L (≥10 x ULN)
Most adverse events reported in CUBICIN clinical trials were mild to moderate in intensity. The most common CUBICIN adverse events were anemia, constipation, diarrhea, nausea, vomiting, injection-site reactions, and headache

Please refer to full Prescribing Information

Home | Terms of Use | Privacy Policy | Site Map

Copyright ©2010 Cubist Pharmaceuticals, Inc., Lexington, MA, USA.
All rights reserved. CUBICIN is a registered trademark of Cubist Pharmaceuticals, Inc.
All other trademarks or registered trademarks are the property of their respective owners.